Deal Intelligence Platform & Services for Global M&A / PE
Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown
French pharmaceutical giant Servier has moved decisively to bolster its targeted therapy pipeline, announcing a definitive agreement to acquire Day One Biopharmaceuticals (NASDAQ: DAWN) in an...
Private equity giant TPG is weighing strategic options for its Southeast Asian healthcare portfolio company, Asia OneHealthcare, including a potential sale or an initial public offering (IPO) that...
In a landmark corporate maneuver testing the boundaries of Japan's evolving corporate governance landscape, the Toyota Group, led by Chairman Akio Toyoda, has successfully orchestrated the...
NEW YORK & PARIS — March 4, 2026 Pasqal Holding SAS, the French quantum computing firm known for its neutral atom technology, is set to transition to the public markets via a definitive business...